For US Healthcare Professionals Full prescribing information Important Safety Information Patient Site Margenza Access Support Request Information

Full Prescribing Information

Request Information

Organizations supporting the
HER2‑positive mBC community

Together, we continue the fight

Find an organization that can help support your patients with HER2‑positive mBC, their loved ones, and caregivers.

Wellness

Emotional

Financial

Community

14 out of 14 results

Breastcancer.org

The mission of Breastcancer.org is to help people make sense of the complex medical information about breast health and breast cancer, so they can make the best decisions for their lives.

Visit Breastcancer.org

CancerCare

CancerCare is the leading national nonprofit organization offering free, professional support services to anyone affected by cancer—including counseling, support groups, educational resources, financial assistance, resource navigation, and more.

Visit CancerCare

Cancer Support Community

The Cancer Support Community (CSC) is a professionally led nonprofit network of cancer support worldwide. CSC, along with its network of Gilda’s Club and CSC partners, provide social and emotional support and educational programming for people impacted by cancer, as well as a free community of support and education available over the phone and online.

Visit Cancer Support Community

The Chrysalis Initiative

The Chrysalis Initiative applies evidence-based strategies to reshape the individual and institutional knowledge, attitudes, and behaviors that impact health outcomes for Black women (and other disparate groups) with breast cancer.

Visit The Chrysalis Initiative

Día de la Mujer Latina

Día de la Mujer Latina promotes healthy behaviors within the underserved Latino community by providing culturally and linguistically proficient education services, early detection screening, and preventative care interventions.

Visit Día de la Mujer Latina

Living Beyond Breast Cancer

Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers live programs and on-demand emotional, practical and evidence-based content.

Over thirty years since its inception, the organization remains committed to creating a culture of acceptance—where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, visit LBBC.ORG or call (855) 807‑6386.

Visit Living Beyond Breast Cancer

Patient Advocate Foundation

The Patient Advocate Foundation provides case management services and financial aid to patients with chronic, life threatening, and debilitating illnesses.

Visit Patient Advocate Foundation

SHARE provides dedicated, experienced support for women facing breast, ovarian, uterine, cervical, or metastatic breast cancer. SHARE is a compassionate community of knowledgeable survivors, women living with cancer, and healthcare professionals.

Visit SHARE

Sharsheret

Through personalized support, Sharsheret improves the lives of Jewish women and families living with or at increased genetic risk for breast or ovarian cancer. This national non-profit organization saves lives through educational outreach programs serving all women and men.

Visit Sharsheret

Tigerlily Foundation

Tigerlily Foundation's mission is to educate, advocate for, empower, and support young women—before, during, and after breast cancer; and to end disparities of age, stage, and color.

Visit Tigerlily Foundation

Touch, The Black Breast Cancer Alliance

Touch, The Black Breast Cancer Alliance drives the collaborative efforts of patients, survivors, advocates, advocacy organizations, health care professionals, researchers, and pharmaceutical companies to work collectively, with accountability, towards the common goal of eradicating Black Breast Cancer.

Visit Touch, The Black Breast Cancer
Alliance

Triage Cancer

Triage Cancer provides free education on the legal and practical issues including finances, insurance, and employment, that may impact individuals diagnosed with cancer and their caregivers.

Visit Triage Cancer

Unite For HER

Unite for HER’s mission is to enrich the health and well-being of those diagnosed with breast and ovarian cancer—for life, by funding and delivering integrative therapies.

Visit Unite For HER

Young Survival Coalition

Young Survival Coalition (YSC) is an international nonprofit dedicated exclusively to young adults diagnosed with breast cancer age 40 and under and their co-survivor support networks. Through educational resources and programming, annual conferences, and local and online support networks, YSC ensures no young adult faces breast cancer alone.

Visit Young Survival Coalition

These organizations are independent and not owned or controlled by MacroGenics, which makes no representations about the services and information they may offer. Their inclusion on this website is not intended as an endorsement of the organization or the services offered, nor is it an indication of the organization’s endorsement of MARGENZA.

MARGENZA Access Support is here to
help your patients with affordability issues

See How

Be in the know

Register for the latest information and updates about MARGENZA

All fields required

First Name: Last Name: Email Address: What best describes you? What type of healthcare professional are you?

I agree to the MacroGenics Terms of Use and that my information will be used in accordance with the MacroGenics Privacy Policy.

Yes, please email me more information about MARGENZA.

Flexibility in chemotherapy
combination choice

Learn More

IMPORTANT SAFETY INFORMATION

WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY

Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function.
Embryo-Fetal Toxicity: Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.

WARNINGS & PRECAUTIONS:

Left Ventricular Dysfunction

Left ventricular cardiac dysfunction can occur with MARGENZA.
In SOPHIA, left ventricular dysfunction occurred in 1.9% of patients treated with MARGENZA.
MARGENZA has not been studied in patients with a pretreatment LVEF value of <50%, a prior history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV.
Withhold MARGENZA for ≥16% absolute decrease in LVEF from pretreatment values or LVEF below institutional limits of normal (or 50% if no limits available) and ≥10% absolute decrease in LVEF from pretreatment values.
Permanently discontinue MARGENZA if LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times due to LVEF decline.
Evaluate cardiac function within 4 weeks prior to and every 3 months during and upon completion of treatment. Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.
Monitor cardiac function every 4 weeks if MARGENZA is withheld for significant left ventricular cardiac dysfunction.

Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, MARGENZA can cause fetal harm when administered to a pregnant woman. Post-marketing studies of other HER2 directed antibodies during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
Verify pregnancy status of women of reproductive potential prior to initiation of MARGENZA.
Advise pregnant women and women of reproductive potential that exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.
Advise women of reproductive potential to use effective contraception during treatment and for 4 months following the last dose of MARGENZA.

Infusion-Related Reactions (IRRs)

MARGENZA can cause IRRs. Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea.
In SOPHIA, IRRs were reported by 13% of patients on MARGENZA plus chemotherapy. Most of the IRRs occur during Cycle 1. Grade 3 IRRs were reported in 1.5% of MARGENZA-treated patients.
Monitor patients during and after MARGENZA infusion. Have medications and emergency equipment to treat IRRs available for immediate use.
In patients experiencing mild or moderate IRRs, decrease rate of infusion and consider premedications, including antihistamines, corticosteroids, and antipyretics. Monitor patients until symptoms completely resolve.
Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with supportive medical therapy as needed. Permanently discontinue MARGENZA in all patients with severe or life-threatening IRRs.

MOST COMMON ADVERSE REACTIONS:

The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).

INDICATION

MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Please see full Prescribing Information, including Boxed Warning.

IMPORTANT SAFETY INFORMATION

WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY

Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function.
Embryo-Fetal Toxicity: Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.

WARNINGS & PRECAUTIONS:

Left Ventricular Dysfunction

Left ventricular cardiac dysfunction can occur with MARGENZA.
In SOPHIA, left ventricular dysfunction occurred in 1.9% of patients treated with MARGENZA.
MARGENZA has not been studied in patients with a pretreatment LVEF value of <50%, a prior history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV.
Withhold MARGENZA for ≥16% absolute decrease in LVEF from pretreatment values or LVEF below institutional limits of normal (or 50% if no limits available) and ≥10% absolute decrease in LVEF from pretreatment values.
Permanently discontinue MARGENZA if LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times due to LVEF decline.
Evaluate cardiac function within 4 weeks prior to and every 3 months during and upon completion of treatment. Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.
Monitor cardiac function every 4 weeks if MARGENZA is withheld for significant left ventricular cardiac dysfunction.

Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, MARGENZA can cause fetal harm when administered to a pregnant woman. Post-marketing studies of other HER2 directed antibodies during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
Verify pregnancy status of women of reproductive potential prior to initiation of MARGENZA.
Advise pregnant women and women of reproductive potential that exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.
Advise women of reproductive potential to use effective contraception during treatment and for 4 months following the last dose of MARGENZA.

Infusion-Related Reactions (IRRs)

MARGENZA can cause IRRs. Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea.
In SOPHIA, IRRs were reported by 13% of patients on MARGENZA plus chemotherapy. Most of the IRRs occur during Cycle 1. Grade 3 IRRs were reported in 1.5% of MARGENZA-treated patients.
Monitor patients during and after MARGENZA infusion. Have medications and emergency equipment to treat IRRs available for immediate use.
In patients experiencing mild or moderate IRRs, decrease rate of infusion and consider premedications, including antihistamines, corticosteroids, and antipyretics. Monitor patients until symptoms completely resolve.
Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with supportive medical therapy as needed. Permanently discontinue MARGENZA in all patients with severe or life-threatening IRRs.

MOST COMMON ADVERSE REACTIONS:

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).

INDICATION

Please see full Prescribing Information, including Boxed Warning.

Organizations supporting the HER2‑positive mBC community

Together, we continue the fight

Be in the know

Register for the latest information and updates about MARGENZA

You are now leaving the MARGENZA® (margetuximab-cmkb) Healthcare Professionals Website.

You are now leaving the MARGENZA® (margetuximab-cmkb) Healthcare Professionals Website.

You are now leaving the MARGENZA® (margetuximab-cmkb) Healthcare Professionals Website.

Organizations supporting the
HER2‑positive mBC community

You are now leaving the MARGENZA^® (margetuximab-cmkb) Healthcare Professionals Website.

You are now leaving the MARGENZA^® (margetuximab-cmkb) Healthcare Professionals Website.

You are now leaving the MARGENZA^® (margetuximab-cmkb) Healthcare Professionals Website.